To enhance the NK population induced by Herpes Simplex virus thymidine kinase (HSV-tk) gene transduction and ganciclovir (GCV) treatment, adenovirus-mediated (Ad
Introduction
Pro-drug activation gene therapy using Herpes Simplex virus thymidine kinase (HSV-tk) gene transduction in combination with ganciclovir (GCV) is under investigation as a potential cancer therapy. Intrinsic to its ability to control growth in a variety of tumor models has been the observation that anti-tumor immunity is induced, as manifest by inhibition of challenge injections or synchronously growing tumors. [1] [2] [3] [4] [5] While the steps involved in the initiation of an immune response following HSV-tk/GCV remain unclear, efforts to enhance this response have involved the empiric addition of cytokines, such as IL-2, to stimulate cytotoxic T cells and GM-CSF to enhance antigen presentation. In some tumor models such combinations have yielded superior results, [6] [7] [8] [9] though in some models no improvement over HSV-tk/GCV was noted. 10 In an orthotopic mouse model of prostate cancer adenovirus-mediated (Ad.) HSVtk/GCV therapy resulted in the induction of natural killer cells (NK) within tumor infiltrating lymphocytes.
11
Performance of gene therapy in mice lacking NKs modestly reduced the impact of Ad.HSV-tk/GCV within the injected primary tumor and completely abrogated systemic growth suppression of pre-established metastatic deposits.
The strategy of combining HSV-tk with IL-12 gene therapy was conceived to exploit the ability of IL-12 to stimulate NK proliferation and cytotoxicity, 12 to thereby further the innate immune response induced by Ad.HSVtk + GCV. Parallel studies had demonstrated the individual growth suppressive ability of adenovirus-mediated IL-12 gene therapy (Ad.IL-12) to result in growth inhibition of both the injected tumor and pre-established metastases in a dose-dependent manner. 13 High-dose IL-12 therapy mediated growth suppression within the primary tumor through induction of innate (neutrophils and NKs) and acquired immunity (T cells), while anti-metastatic activity was mediated through up-regulation of Fas thereby enhancing sensitivity to FasL transactivation by lung epithelial cells. 13 The combination of Ad.HSV-tk and
Gene Therapy
Ad.IL-12 illustrated the superior benefits of combination therapy to result in primary tumors which were 85-90% smaller than control tumors and a 75% reduction in the number of pre-established lung metastases. 14 Since prior work had noted the ability of both therapies to independently direct systemic growth suppression, 11, 13 the strength of systemic anti-tumor activity mediated by combination therapy was tested by increasing the metastatic tumor burden to a point where neither Ad.HSVtk/GCV nor Ad.IL-12 had a significant effect. In this setting, combination gene therapy continued to suppress the number of lung metastasis by 50%. 14 In the present report, the underlying mechanisms of combination therapy are elucidated. Ad.HSV-tk/GCV + Ad.IL-12 enhanced NK activity, but performance of therapy in the absence of NK cells negatively impacted only on systemic growth suppression. TUNEL analysis noted the induction and maintenance of apoptosis by combination therapy. The resulting studies noted the independent ability of HSV-tk/GCV and IL-12-induced IFN-␥ to up-regulate tumor cell expression of FasL and Fas, respectively. Blockage of Fas/FasL interactions both in vitro and in vivo significantly blunted the effects of combination therapy. Performance of combination therapy in FasL knockout mice maintained the superior results of combination therapy to that experienced in wild-type mice, indicating that tumor cell, not host cell, FasL was responsible for Fas transactivation.
Results
Assay of TIL harvested post-vector injection noted lytic activity in the Ad.HSV-tk/GCV, Ad.mIL-12 and Ad.HSV-tk/GCV + Ad.mIL-12 groups (Figure 1a and b) . Induction of NK activity was noted initially in both groups treated with Ad.HSV-tk/GCV, peaking on day 4 post-vector injection and demonstrating superior activity for combination therapy (P = 0.006, t test, Ad.HSV-tk + GCV versus Ad.HSV-tk + GCV + Ad.mIL-12). As noted by past-experience, 13 Ad.mIL-12 therapy induced NK activity by day 8. TIL from both Ad.HSV-tk/GCV and combination gene therapy lysed RM-1s in a similar pattern, peaking on day 6 post-vector injection which again illustrated the superiority of combination gene therapy (P = 0.0054, t test, Ad.HSV-tk + GCV versus Ad.HSV-tk + GCV + Ad.mIL-12). The functional significance of this presumed NK response was explored by performing combination gene therapy in mice depleted of CD4 and CD8 T cells or NKs in the pre-established metastasis model. Assay over the first 8 days post-vector injection failed to demonstrate a negative impact with regard to primary tumor growth suppression following removal of T cells and NKs. In each instance tumors remained over five times smaller than control tumors (P Ͻ 0.0001 for all conditions of combination therapy versus control, t test) (Figure 1c) . However, suppression of pre-established metastases was completely lost in mice depleted of NK cells (P = 0.85 versus control, t test), while the 50% reduction seen with combination treatment continued in mice depleted of T cells (P = 0.0001 versus control, t test) (Figure 1d ).
Serial assay for apoptosis noted enhanced activity in tumors treated with combination gene therapy, lasting for 8 days post-vector injection (Figure 2 ). By the 2nd day post-vector, all three treatment groups resulted in increased apoptosis manifest by an eight times higher level for combination therapy compared with control, though appearing to be additive of the independent effects of Ad.mIL-12 and Ad.HSV-tk/GCV (P = 0.005, combination therapy versus control; P = 0.04, combination therapy versus Ad.mIL-12; P = 0.13, combination therapy versus Ad.HSV-tk/GCV, t test). In succeeding days apoptosis relating to Ad.mIL-12 resolved to control levels, while Ad.HSV-tk/GCV remained at approximately twice control and combination at four times control, (P Ͻ 0.05 combination therapy versus control for days 4-8; P = 0.005, combination therapy versus Ad.HSV-tk/GCV for days 4 and 6, t test).
Studies with Ad.mIL-12 therapy alone in the RM-1 model noted measurable serum levels of IFN-␥, which increased tumor cell expression of Fas both in vitro and in vivo ( Figure 3) . 13, 15 In contrast IFN-␥ had little effect on FasL expression (Figure 3 ). Likewise, escalating doses of IL-12, 100× higher than that measured in the serum of Ad.mIL-12-treated animals, 13 had no effect on Fas/FasL expression ( Figure 3 ). Since HSV-tk/GCV has been reported to influence Fas and FasL expression in other tumor models, 16 ,17 the influence of Ad.HSV-tk/GCV was ascertained in RM-1 cells. FACS analysis of Ad.HSV-tk infected cells 24 h after exposure to GCV noted marked expression of FasL to approximately 50%. This correlated with the transduction efficiency of 40-50% at the vector dose used. 18 Ad.HSV-tk/GCV had little effect on Fas expression ( Figure 3 ). Exposure to vector or GCV alone likewise had minimal influence on Fas/FasL expression (data not shown). By 48 h after GCV therapy, the number of surviving cells was reduced to 10-15%, with Fas/FasL resembling that of control (data not shown). A hypothesis was thus generated that the superior tumor control was due to the ability of IFN-␥, produced in response to Ad.mIL-12, to enhance Fas expression and the ability of Ad.HSV-tk/GCV to enhance FasL, resulting in Fas transactivation and apoptosis within the primary tumor.
In vitro cell kill from Ad.HSV-tk/GCV at MOI of 25 is approximately 80% (Figure 4a ). The addition of 25 U/ml IFN-␥, a dose without growth suppressive activity itself, added no additional benefit at this vector dose. However, at progressively lower MOI the killing ability of Ad.HSVtk/GCV lessened in a dose-dependent manner, but the addition of IFN-␥ maintained maximum cell kill to the MOI of 6.25 (P = 0.026, Ad.HSV-tk + GCV + IFN-␥ versus AdHSV-tk + GCV, Mann-Whitney). The addition of antiFasL IgG at the time of GCV exposure blocked this effect such that the level of cell survival was identical to that of Ad.HSV-tk/GCV alone at all MOI tested (Ad.HSVtk/GCV + IFN-␥+ anti-FasL IgG versus Ad.HSV-tk/GCV P = 0.63, Mann-Whitney; Ad.HSV-tk/GCV + IFN-␥+ antiFasL IgG versus Ad.HSV-tk/GCV + IFN-␥, P = 0.0015, Mann-Whitney) (Figure 4b) .
In vivo blockage of Fas/FasL interactions was achieved by co-inoculation with Ad.sFasIg at the time of Ad.HSVtk + AdmIL-12 injection. Use of this vector significantly reduced the growth suppression of combination therapy such that tumors were three times larger than expected (P Ͻ 0.0001, combination therapy versus combination therapy + Ad.sFasIg) (Figure 4c ). In addition, blockage of Fas/FasL interactions was associated with a loss of apoptosis generated by combination therapy. By day 8 post-vector apoptosis in combination therapy treated tumors was lowered to that of controls: 1.73 ± 0.22 apop- 
Discussion
A variety of gene therapy strategies for the treatment of cancer have been developed, generally through one of two basic methods: local growth suppression via direct inoculation of tumor suppressor or pro-drug activation genes (ie p53 or HSV-tk) or systemic growth inhibition following local gene expression (ie antiangiogenesis gene therapy or gene-modified immunotherapy). A major limitation of in situ approaches is the low efficiency of vector uptake following direct injection, yielding it difficult to establish uniform cure rates. Attempts to bypass this problem have utilized intricate injection schemes, replication-competent vectors, and 'bystander effects', whereby more cells are killed than are transduced. The combination of Ad.HSV-tk/GCV and Ad.mIL-12 was chosen to exploit the ability of IL-12 to enhance proliferation and cytotoxicty of the NK response induced by HSV-tk + GCV in this model to improve both local and systemic
Figure 3 FACS analysis of Fas/FasL expression following (a) IL-12, (b) IFN-␥, and (c) HSV-tk/GCV therapy. Plated RM-1 cells were exposed to 25 U/ml IFN-␥, 200 ng/ml IL-12, 50 MOI of Ad.HSV-tk or PBS. For (a) and (b), cells were prepared for immunostaining 24 h later with anti-Fas, antiFasL, or control antibodies and FACS analysis. Cells exposed to Ad.HSV-tk were randomized to GCV or PBS treatments the following day and prepared for immunohistochemistry 24 h after GCV/PBS. For each graph the dotted line represents exposure to PBS and solid line the treatment condition.
growth suppression. Studies of TIL from combination therapy-treated mice indicated an enhancement of NK activity from Ad.HSV-tk/GCV alone by adding Ad.mIL-12. The in vivo relevance of this population was validated by a near complete loss of growth inhibition of pre-established metastatic lesions in the absence of NKs. Indeed, at the metastatic tumor burden tested the individual therapies had no effect on pre-established metastases, 14 indicating the strong systemic growth suppressive capabilities of this NK population.
While the control of disseminated lesions was dependent on NKs, the enhanced growth control of the injected tumor was not directly related to an immune response. Studies noted the independent ability of IFN-␥ and HSVtk/GCV to influence Fas/FasL. RM-1 cells express both Fas and FasL (Fas approximately 25-30% and FasL approximately 10-15%); IFN-␥at doses well below that measured in serum of Ad.mIL-12-treated animals to upregulated Fas in vitro consistent with the literature. 13, 15 In vivo increased Fas expression could be seen in Ad.mIL-12 injected tumors as early as 2 days post-vector, lasting to at least the 8th day (Ref. 13 and unpublished observations). In contrast high doses (up to 200 ng/ml) of recombinant IL-12 resulted in neither cytotoxicity 13 nor changes in Fas/FasL expression. In parallel, it has been shown that HSV-tk + GCV therapy may also influence Fas/FasL expression. 16, 17 In a human neuroblastoma cell line HSV-tk/GCV resulted in apoptosis via FasL-independent aggregation of upregulated Fas. 17 In four different cancer cell lines HSV-tk/GCV increased expression of both Fas and FasL which mediated some degree of bystander killing, as documented by a reduction in HSVtk/GCV effects by blockage of Fas/FasL interactions. 17 In three of four cases, Fas expression was more pronounced In vitro the addition of IFN-␥, at a dose which itself does not impact on RM-1 cell growth, to Ad.HSV-tk + GCV, maintained maximum cell kill at a four-fold lower vector dose, indicating the presence of strong cooperative activities. The co-administration of an anti-FasL antibody reverses this phenomenon, clearly defining a role for Fas/FasL activities in this enhanced killing. Likewise, in vivo blockage of Fas/FasL results in a significant loss of growth suppression and apoptosis within the primary tumor, demonstrating that a proportion of enhancement due to combination therapy is related to Fas/FasL interactions. The correlation between loss of growth suppression and the decrease in apoptosis noted following use of Ad.sFasIg would suggest that apoptosis through Fas transactivation is the mechanism of cell death. While the hypothesis had placed the source of FasL as tumor Gene Therapy cells infected with Ad.HSV-tk and exposed to GCV, FasL could be derived from host sources in vivo such as immune cells (NK and/or T cells) or within prostate tissues. 19 Therefore, to further delineate the source of FasL, combination gene therapy was performed in FasL KO mice. As noted in wild-type mice, growth suppression with Ad.HSV-tk/GCV + Ad.mIL-12 resulted in a nearly 90% size differential with loss of activity achieved with the addition of Ad.sFasIg. Therefore, a tumor cell-mediated bystander effect is defined through Ad.HSV-tk/GCV and Ad.mIL-12-IFN-␥ independent induction of Fas and FasL expression to result in further killing through Fas transactivation. Both in vitro and in vivo studies illustrate the power of this phenomenon in combination gene therapy and characterize an additional approach to more efficiently kill cancer cells within the confines of an injected tumor.
Materials and methods

Cell lines
The RM-1 cell line (passage 14-17) is a well-characterized mouse prostate cancer cell line, established from a ras/myc-induced primary tumor derived in the mouse prostate reconstitution (MPR) model system in C57BL/6 mice (obtained from Dr TC Thompson, Baylor College of Medicine, Houston, TX, USA). 20, 21 Cells used in the reported studies were grown in DMEM with 10% FBS and penicillin (100 units/ml) and streptomycin (100 mg/ml). YAC-1 is a NK cell-sensitive mouse lymphoma cell line, maintained in RPMI 1640 with 10% FBS. Routine passaging was carried out using cell dissociation media. All reagents pertaining to cell culture were obtained from Sigma (Sigma Chemical, St Louis, MO, USA).
Adenovirus vectors
Replication-defective E1 deleted recombinant adenovirus vectors expressing HSV-tk, mouse IL-12 (mIL-12), and sFasIg, all under control of the Rous sarcoma virus promoter (RSV), were constructed as previously described. 13, 22, 23 The Ad.sFasIg construct links the extracellular domain of Fas to the Fc region of mouse IgG2a. DL312 is an E1-deleted adenovirus without a transgene and was used as vector control. Virus titer for in vivo use was determined by plaque assay in 293 cells and expressed as plaque-forming units (p.f.u.) following expansion and double cesium gradient ultracentrifugation purification.
In vivo gene therapy
Orthotopic primary tumors and synchronous metastases were established as previously described.
11 Briefly, at the same sitting 7500 RM-1 cells were injected into the dorsolateral prostate and 7500 cells were injected via the dorsolateral tail vein. Primary tumors were injected with vector 6 days later, at which time the lungs contain microscopic metastases. The therapeutic dose of Ad.HSV-tk had been previously established at 5 × 10 8 p.f.u., 5 while Ad.mIL-12 was 3.3 × 10 9 p.f.u. Mice were killed 14 days after tumor cell inoculation. The primary tumors were removed, the bladder and seminal vesicles excised, and a wet weight obtained for each tumor. The lungs were likewise removed, placed in Bouin's solution, and changed to 70% ethanol 1 h later. Visible lung metastases were counted with the aid of a dissecting microscope.
In vitro cytotoxic assays
At designated time-points, mice were killed, and the primary prostate tumors removed. Tumor infiltrating lymphocytes were extracted and prepared for chromium ( 51 Cr) release assay, as previously described. 11 Briefly, pooled tumors from each treatment group were mechanically lysed and serially purified by gravity precipitation to remove tumor debris. Following treatment with red cell lysis buffer (Sigma) and passage through cotton wool pipettes, remaining viable lymphocytes were counted and exposed to 51 Cr-loaded targets at various E:T ratios. The percentage lysis was calculated as (experimental release Ϫ spontaneous)/(maximal release Ϫ spontaneous release) from the gamma counter measurements of supernatant harvested by the Skatron system (Skatron Instruments, Sterling, VA, USA).
In vivo depletions
Mice were depleted of specific lymphocyte populations by i.p. injections of antibodies beginning 1 day before Ad./HSV-tk + Ad.mIL-12 injection on a schedule as previously reported:
11 CD4 T cells with purified ascites from hybridoma GK 1.5 (American Type Culture Collection, Rockville, MD, USA), CD8 T cells with purified ascites from hybridoma 2.43 (American Type Culture Collection), NK cells with anti-AsialoGM1 IgG (Wako Chemicals, Reston, VA, USA), and controls with rabbit IgG (DAKO, Carpinteria, CA, USA) and rat IgG (Accurate Chemical and Scientific, Westbury, NY, USA). Control mice were given a total of 20 g of IgG to equal that given to CD4/CD8 mice. All mice were killed on day 14 with the removal of primary tumor and lungs with appropriate examination carried out as outlined above.
Apoptosis assay
Tumors representing each treatment arm, Ad.HSVtk/PBS, Ad.HSV-tk/GCV, Ad.mIL-12, and Ad.HSVtk/GCV + Ad.mIL-12, were harvested every other day beginning on day 2 after vector injection to 8 days after vector injection. In addition, tumors from mice treated with Ad.sFasIg alone or with combination therapy were killed 14 days after tumor inoculation and were similarly prepared. After fixation in formalin, parrafin embedding, and sectioning, tissue samples were prepared for TUNEL assay, according to the maunfacturer's instructions (Trevigne Industries, Gaithersburg, MD, USA). Individual tumor sections were scanned along the long and short axes at high power (×400) with a light microscope. The number of apoptotic bodies was counted and reported as average number of bodies per high power field.
FACS assay of Fas/FasL expression
Plated RM-1 cells were exposed to either mouse IFN-␥ (100 U/ml, Pharmingen, San Diego, CA, USA), mouse IL-12 (1-200 ng/ml, Pharmingen) or Ad.HSV-tk at a multiplicity of infection (MOI: number of p.f.u. per cell) of 50. This vector dose correlates with approximately 50% cell transduction. 18 Twenty-four hours following the addition of IFN-␥, cells were removed with cell dissociation medium and prepared for immunohistochemistry. Cells exposed to vector were randomized 24 h later to saline (PBS) or GCV (10 g/ml, Roche Laboratories, Nutley, NJ, USA). The following day, single cell suspensions were randomized to exposure to anti-FasL IgG, anti-Fas IgG, or iso-control IgG (Pharmingen) for 45 min on ice. Following washing in PBS, cells were exposed to PE-labeled anti-hamster IgG (Pharmingen) for 30 min followed by FACS analysis.
In vitro gene therapy
Plated RM-1 cells were exposed to escalating MOI of Ad.HSV-tk for 1 h. Twenty-four hours later, wells were randomized to receive PBS, GCV (10 g/ml), mouse IFN-␥ (25 U/ml) or GCV + IFN-␥. Disassociated viable cells as per trypan blue exclusion assay were counted the following day. Blockage of FasL/Fas interactions was achieved by adding anti-mouse FasL IgG or isotype control IgG (Pharmingen) to designated wells at the same time as the addition of PBS/GCV/IFN-␥.
Blockage of Fas/FasL interactions in vivo
Interference of Fas/FasL transactivation in vivo was achieved by co-inoculation with Ad.sFasIg, as previously described. 13 In the synchronous metastasis model on day 6, primary tumors were injected with either 1 × 10 9 p.f.u. DL312 or Ad.sFasIg, followed by randomization for treatment with combination gene therapy or control vector. Mice were killed on the 8th day after vector injection and the effects of gene therapy measured in both the primary tumor and lungs as described earlier. Further evaluation of Fas/FasL activities were carried out by repeating the same experiments in FasL knockout mice (Jackson Laboratory, Bar Harbor, ME, USA).
